

# Oklahoma Health Care Authority

Drug Utilization Review Board  
(DUR Board)

Meeting – June 10, 2015 @ 4:00 p.m.

Oklahoma Health Care Authority  
4345 N. Lincoln Blvd.  
Oklahoma City, Oklahoma 73105

---

## AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

**1. Call To Order**

- A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

**2. Public Comment Forum**

- A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

**3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A**

- A. April 8, 2015 DUR Minutes – Vote  
B. April 8, 2015 DUR Recommendations Memorandum

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

**4. Update on Medication Coverage Authorization Unit/Chronic Medication Adherence Program Update – See Appendix B**

- A. Medication Coverage Activity for April 2015  
B. Pharmacy Help Desk Activity for April 2015  
C. Medication Coverage Activity for May 2015  
D. Pharmacy Help Desk Activity for May 2015  
E. Chronic Medication Adherence Program Update

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

**5. Action Item – Vote to Prior Authorize Tanzeum™ (Albiglutide), Trulicity™ (Dulaglutide), Cycloset® (Bromocriptine), Jardiance® (Empagliflozin), Invokamet™ (Canagliflozin/Metformin), Xigduo™ XR (Dapagliflozin/Metformin Extended-Release), Glyxambi® (Empagliflozin/Linagliptin), Afrezza® (Insulin Human Inhalation Powder), and Toujeo® (Insulin Glargine) – See Appendix C**

- A. College of Pharmacy Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

**6. Action Item – Vote to Prior Authorize Ruconest® (C1 Esterase Inhibitor) – See Appendix D**

- A. College of Pharmacy Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

**7. Action Item – Vote to Prior Authorize Hemangeol™ (Propranolol Oral Solution), Sotylize™ (Sotalol Oral Solution), and Prestalia® (Perindopril/Amlodipine) – See Appendix E**

- A. College of Pharmacy Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

- 8. Annual Review of Atypical Antipsychotic Medications and 30-Day Notice to Prior Authorize Invega Trinza™ (3-Month Paliperidone Palmitate Injection) – See Appendix F**
- A. Current Prior Authorization Criteria
  - B. Utilization of Atypical Antipsychotics
  - C. Prior Authorization of Atypical Antipsychotic Medications
  - D. Market News and Updates
  - E. Invega Trinza™ (3-Month Paliperidone Palmitate Injection) Product Summary
  - F. College of Pharmacy Recommendations
  - G. Utilization Details of Atypical Antipsychotic Medications

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

- 9. 30-Day Notice to Prior Authorize Cholbam™ (Cholic Acid) – See Appendix G**
- A. Introduction
  - B. Cholbam™ (Cholic Acid) Product Summary
  - C. College of Pharmacy Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

- 10. 30-Day Notice to Prior Authorize Natpara® (Parathyroid Hormone) – See Appendix H**
- A. Introduction
  - B. Natpara® (Parathyroid Hormone) Product Summary
  - C. College of Pharmacy Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

- 11. Annual Review of ADHD & Narcolepsy Medications and 30-Day Notice to Prior Authorize Zenedi® (Dextroamphetamine), Evekeo™ (Amphetamine), and Aptensio XR™ (Methylphenidate Extended-Release) – See Appendix I**
- A. Current Prior Authorization Criteria
  - B. Utilization of ADHD & Narcolepsy Medications
  - C. Prior Authorization of ADHD & Narcolepsy Medications
  - D. Market News and Updates
  - E. Product Summaries
  - F. Binge Eating Disorder (BED) Summary
  - G. College of Pharmacy Recommendations
  - H. Utilization Details of ADHD & Narcolepsy Medications

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

- 12. Annual Review of Otic Anti-Infectives and 30-Day Notice to Prior Authorize Xtoro™ (Fluoroquinolone) – See Appendix J**
- A. Current Prior Authorization Criteria
  - B. Utilization of Otic Anti-Infectives
  - C. Prior Authorization of Otic Anti-Infectives
  - D. Market News and Updates
  - E. Xtoro™ (Fluoroquinolone) Product Summary
  - F. College of Pharmacy Recommendations
  - G. Utilization Details of Otic Anti-Infectives

Items to be presented by Dr. Lorg, Dr. Muchmore, Chairman:

- 13. Annual Review of Insomnia Medications and 30-Day Notice to Prior Authorize Hetlioz® (Tasimelteon) and Belsomra® (Suvorexant) – See Appendix K**
- A. Current Prior Authorization Criteria
  - B. Utilization of Insomnia Medications
  - C. Prior Authorization of Insomnia Medications
  - D. Market News and Updates

- E. Product Summaries
- F. College of Pharmacy Recommendations
- G. Utilization Details of Insomnia Medications

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

**14. Annual Review of Cephalosporin Antibiotics & Systemic Antibiotic Special Formulations and 30-Day Notice to Prior Authorize Avycaz™ (Ceftazidime/Avibactam) and Zerbaxa™ (Ceftolozane/Tazobactam) – See Appendix L**

- A. Introduction
- B. Current Prior Authorization Criteria
- C. Utilization of Cephalosporin Antibiotics & Systemic Antibiotic Special Formulations
- D. Prior Authorization of Cephalosporin Antibiotics & Systemic Antibiotic Special Formulations
- E. Cephalosporin Utilization Evaluation
- F. Market News and Updates
- G. Product Summaries
- H. College of Pharmacy Recommendations
- I. Utilization Details of Cephalosporin Antibiotics
- J. Utilization Details of Systemic Antibiotic Special Formulations

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

**15. 30-Day Notice to Prior Authorize Copaxone® (Glatiramer Acetate) 40mg/mL – See Appendix M**

- A. Introduction
- B. Current Prior Authorization Criteria
- C. Copaxone® (Glatiramer Acetate) Utilization
- D. Market News and Updates
- E. Discussion
- F. College of Pharmacy Recommendations
- G. Utilization Details of Copaxone® (Glatiramer Acetate)

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman:

**17. FDA and DEA Updates – Appendix N**

Items to be presented by Dr. Muchmore, Chairman:

**18. Adjournment**